Amphastar Pharmaceuticals, Inc. (AMPH) — Financial statements
Income statement, balance sheet, and cash flow for Amphastar Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 720↓1.7% | 732↑13.6% | 644↑29.1% | 499↑14.0% | 438 | |
| Cost of Revenue | 364↑1.6% | 358↑22.1% | 293↑17.3% | 250↑5.1% | 238 | |
| Gross Profit | 356↓4.8% | 374↑6.5% | 351↑41.1% | 249↑24.6% | 200 | |
| Operating Expenses | ||||||
| R&D Expenses | 86↑16.1% | 74↑0.2% | 74↓1.4% | 75↑22.7% | 61 | |
| General & Administrative Expenses | 86↑51.5% | 57↑10.1% | 52↑14.4% | 45↓12.4% | 51 | |
| Selling & Marketing Expenses | 44↑16.1% | 38↑31.0% | 29↑34.0% | 22↑23.1% | 17 | |
| SG&A Expenses | 130↑37.3% | 95↑17.6% | 80↑20.7% | 67↓3.4% | 69 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 216↑28.0% | 168↑9.3% | 154↑9.0% | 141↑8.9% | 130 | |
| Total Costs & Expenses | 579↑10.1% | 527↑17.7% | 447↑14.3% | 391↑6.4% | 368 | |
| Operating Results | ||||||
| Operating Income | 140↓31.7% | 205↑4.3% | 197↑83.2% | 107↑53.8% | 70 | |
| Depreciation & Amortization | 0.00↓100.0% | 57↑36.9% | 42↑47.8% | 28↑6.6% | 27 | |
| EBITDA | 149↓46.2% | 277↑15.4% | 240↑64.4% | 146↑31.0% | 112 | |
| EBIT | 149↓32.3% | 220↑10.9% | 199↑68.4% | 118↑38.7% | 85 | |
| Interest & Other Income | ||||||
| Net Interest Income | -17↑14.8% | -20↑9.1% | -22↓4033.1% | -0.53↓84.9% | -0.28 | |
| Interest Income | 9↓18.2% | 11↑94.4% | 5↑313.2% | 1↑119.8% | 0.60 | |
| Interest Expense | 25↓16.0% | 30↑11.7% | 27↑1371.2% | 2↑108.6% | 0.89 | |
| Non-Operating Income | -9↑40.8% | -15↓860.0% | -2↑85.3% | -10↑31.4% | -15 | |
| Other Income / Expenses | -17↓3.4% | -16↑41.2% | -28↓474.8% | 7↓47.6% | 14 | |
| Income Before Tax | 124↓34.7% | 189↑11.7% | 169↑47.5% | 115↑36.9% | 84 | |
| Income Tax Expense | 26↓14.0% | 30↓6.8% | 32↑35.6% | 23↑13.8% | 21 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 98↓38.5% | 160↑16.0% | 138↑50.5% | 91↑44.4% | 63 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 98↓38.5% | 160↑16.0% | 138↑50.5% | 91↑47.1% | 62 | |
| Bottom-Line Net Income | 98↓38.5% | 160↑16.0% | 138↑50.5% | 91↑47.1% | 62 | |
| EPS (Basic) | 2.10↓36.2% | 3.29↑15.4% | 2.85↑51.6% | 1.88↑44.6% | 1.30 | |
| EPS (Diluted) | 2.03↓33.7% | 3.06↑17.7% | 2.60↑49.4% | 1.74↑39.2% | 1.25 | |
| Weighted Average Shares | 47↓3.5% | 48↑0.3% | 48↓0.6% | 49↑1.6% | 48 | |
| Weighted Average Diluted Shares | 48↓7.4% | 52↓1.8% | 53↑1.1% | 52↑5.3% | 50 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.